In this episode of Behind the Breakthroughs, Michael Severino, MD, discusses the approaches for developing "genome writers" at Tessera Therapeutics, where he joined as CEO in 2022, and the advantages of performing in vivo genome editing over ex vivo approaches. Severino explains where the company is in utilizing its genome writing platform to perform edits in vivo on its journey toward the clinic.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack


Hosted on Acast. See acast.com/privacy for more information.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Inside Precision Medicine. Innehållet i podden är skapat av Inside Precision Medicine och inte av, eller tillsammans med, Poddtoppen.